Brief: Cytokinetics Launches Myqorzo® (Aficamten) In European Union, With First Commercial Availability In Germany
01/06/2026 12:48
BRIEF-Cytokinetics Launches Myqorzo® (Aficamten) In European Union, With First Commercial Availability In Germany June 1 (Reuters) - Cytokinetics Inc CYTK.O:
CYTOKINETICS LAUNCHES MYQORZO® (AFICAMTEN) IN EUROPEAN UNION, WITH FIRST COMMERCIAL AVAILABILITY IN GERMANY
Source text: ID:nGNX4RLvR3
Further company coverage: CYTK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytokinetics, Incorporated
See all newsBrief: Cytokinetics To Announce Third Quarter Results On November 4, 2026
Brief: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Cytokinetics Announces Additional Data From Acacia-Hcm Presented At The Hfsa Annual Scientific Meeting 2026
Brief: Cytokinetics Launches Aspen-Hcm A Real-World Study Evaluating Myqorzo® (Aficamten) In Symptomatic Obstructive Hypertrophic Cardiomyopathy
U.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech